Patients with advanced or metastatic renal cell carcinoma (RCC) who have not previously received treatment with vascular endothelial growth factor-tyrosine kinase inhibitors (VEGF-TKIs) may potentially benefit from treatment with the TKI pazopanib, according to interim analysis results of the PARACHUTE* trial presented at ESMO Asia 2019.